Zevra Therapeutics (NASDAQ:ZVRA) Shares Up 4.6% – Here’s Why

by · The Markets Daily

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report)’s share price rose 4.6% on Wednesday. The stock traded as high as $11.03 and last traded at $11.22. Approximately 121,339 shares traded hands during trading, a decline of 90% from the average daily volume of 1,265,104 shares. The stock had previously closed at $10.73.

Analyst Upgrades and Downgrades

ZVRA has been the subject of a number of analyst reports. Maxim Group increased their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Guggenheim decreased their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. BTIG Research reduced their price target on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday, July 27th. Finally, William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Buy” and an average price target of $27.14.

View Our Latest Report on ZVRA

Zevra Therapeutics Trading Up 4.2%

The company has a 50-day moving average of $11.43 and a 200-day moving average of $11.34. The firm has a market capitalization of $663.87 million, a price-to-earnings ratio of 12.15 and a beta of 0.98.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The firm had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. On average, research analysts forecast that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, Director Corey Watton sold 12,300 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the sale, the director owned 1,800 shares in the company, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Zevra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC bought a new stake in Zevra Therapeutics during the second quarter worth approximately $28,000. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Zevra Therapeutics in the fourth quarter valued at $53,000. WINTON GROUP Ltd lifted its position in shares of Zevra Therapeutics by 49.0% during the 2nd quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock valued at $349,000 after acquiring an additional 8,001 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Zevra Therapeutics by 5.2% during the 2nd quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock worth $2,359,000 after acquiring an additional 8,121 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of Zevra Therapeutics during the 2nd quarter worth $150,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.

Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.

Read More